Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis

BackgroundVedolizumab is a humanized monoclonal antibody targeting the α4β7 integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4+ and CD8+ memory T-lymphocyte su...

Full description

Bibliographic Details
Main Authors: Maria Gonzalez-Vivo, Minna K. Lund Tiirikainen, Montserrat Andreu, Agnes Fernandez-Clotet, Alicia López-García, Francisca Murciano Gonzalo, Lourdes Abril Rodriguez, Carmen de Jesús-Gil, Ester Ruiz-Romeu, Lídia Sans-de San Nicolàs, Lluis F. Santamaria-Babí, Lucía Márquez-Mosquera
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Medicine
Subjects:
inflammatory bowel disease
ulcerative colitis
biological therapy
integrins
T lymphocytes
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.837294/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.837294/full

Similar Items